Progressive multiple sclerosis (MS) is a severely disabling neurological condition, and an
effective treatment is urgently needed. Recently, high-dose biotin has emerged as a …

Background No treatments have been approved for primary progressive multiple sclerosis.
Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is effective in relapse …

Multiple sclerosis (MS) is a chronic inflammatory neurological disease of the CNS that goes
along with demyelination and neurodegeneration. It is probably caused by an autoimmune …

Background: Several reports indicate changes to prevalence, incidence, female-to-male
ratio in multiple sclerosis. Diagnostic criteria, course definitions and clinical management of …

Introduction Antibodies against neurofascin, an axo-glial protein located around the node of
Ranvier, have been shown to contribute to axonal pathology both in vitro and in …

Medicines used for Multiple Sclerosis – A Health Technology Assessment Page 1 Medicines
used for Multiple Sclerosis –AHealth Technology Assessment 2016 Page 2 Title Medicines used …

New Zealand is a high risk region for multiple sclerosis (MS). The aim of this study was to
investigate demographic, clinical and temporal factors associated with disability status in the …

Multiple Sclerosis is a chronic inflammatory demyelinating disorder of the central nervous
system. 1 H-MRS provides us with additional information on the chemical pathology within …

In multiple sclerosis (MS), environmental factors and genetic traits cooperate in the induction
of the chronic activation of immune cells to produce the brain pathology. Epidemiology has …

To date, there have been significant advances in the use of magnetic resonance imaging
(MRI) in the initial diagnostic work-up of patients suspected of having MS and also in the …